Model update after FY23 as Agfa is undergoing a life-changing transformation to become a future-proof, profitable company with a mission. Agfa aims a) to improve patients' lives by contributing to the quality of diagnosis; b) participate in the development of green hydrogen to help decarbonise the world; c) develop innovative digital printing solutions that reduce the environmental footprint.
Correction: The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines - regulated information CORRECTION ONLY IN DUTCH VERSION Regulated information – March 13, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines HealthCare IT: Strong improvement in profitabilityContinued investments in innovative solutions Digital Print & Chemicals: Growing ZIRFON business started to contribute to profitabilityProfitable growth for Digital Print in spite ...
Correction: De Agfa-Gevaert Groep in 2023: EBITDA van de Groep 52% hoger, onder impuls van de groeimotoren - gereglementeerde informatie CORRECTIE: in eerste tabel waren de omzet en EBITDA van Digital Print & Chemicals en Radiology Solutions foutief ingevuld Gereglementeerde informatie – 13-03-2024 - 7:45 uur CET De Agfa-Gevaert Groep in 2023: EBITDA van de Groep 52% hoger, onder impuls van de groeimotoren HealthCare IT: Sterke verbetering rendabiliteitVoortdurende investeringen in innovatieve oplossingen Digital P...
In FY23, the growth engines of Agfa more than compensated for the decline of the traditional film activities, which were under pressure from challenging economic conditions (including adverse currency effects and the weakening economy in China) and geopolitical circumstances. We welcome that FY23 Agfa's growth engines performed well. Agfa indicated it has made strong progress in all of its growth engines, with the launch of its HealthCare IT cloud and web streaming activities, its strategic par...
The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines - regulated information Regulated information – March 13, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in 2023: Group EBITDA increases by 52%, powered by its growth engines HealthCare IT: Strong improvement in profitabilityContinued investments in innovative solutions Digital Print & Chemicals: Growing ZIRFON business started to contribute to profitabilityProfitable growth for Digital Print in spite of subdued equipment investment climateFilm activit...
De Agfa-Gevaert Groep in 2023: EBITDA van de Groep 52% hoger, onder impuls van de groeimotoren - gereglementeerde informatie Gereglementeerde informatie – 13-03-2024 - 7:45 uur CET De Agfa-Gevaert Groep in 2023: EBITDA van de Groep 52% hoger, onder impuls van de groeimotoren HealthCare IT: Sterke verbetering rendabiliteitVoortdurende investeringen in innovatieve oplossingen Digital Print & Chemicals: Groeiende ZIRFON-activiteiten begonnen bij te dragen aan rendabiliteitRendabele groei voor Digital Print ondanks getem...
Jeroen Spruyt appointed as President of Agfa’s Radiology Solutions division Jeroen Spruyt appointed as President of Agfa’s Radiology Solutions division Mortsel, Belgium - March 13, 2024 – 7:45 a.m. CETEffective March 13, 2024, Jeroen Spruyt will assume the position of President of Agfa’s Radiology Solutions division. He will also join Agfa’s Executive Management Team. Jeroen Spruyt holds a degree in Applied Economics, complemented by an MBA from Vlerick Business School. Through his career in logistics and his pivotal role as co-founder and board me...
Jeroen Spruyt benoemd tot President van Agfa’s divisie Radiology Solutions Jeroen Spruyt benoemd tot President van Agfa’s divisie Radiology Solutions Mortsel, België – 13 maart 2024 – 7:45 a.m. CETOp 13 maart 2024 neemt Jeroen Spruyt de functie van President van Agfa’s divisie Radiology Solutions op zich. Hij wordt ook lid van Agfa’s Executive Management Team. Jeroen haalde een diploma Toegepaste Economische Wetenschappen, aangevuld met een MBA van de Vlerick Business School. Door zijn carrière in de logistiek en zijn cruciale rol als medeoprichter...
• Agfa published its FY23 results which came in above CSS and DP expectations. Healthcare IT shows good improvement in profitability, with adj. EBIT landing c.30% above estimates. Radiology had a better Q4 than anticipated as well• Management guides for continued growth in revenues and profitability in 2024 with a slower H1 followed by a stronger H2, in line with what we expected• Despite the ST uncertainty, based on the expected positive earnings momentum, future growth prospects with growth en...
We maintain our Outperform rating with an updated (DCF based) price target of €50.5 per share (was €46). The improved (and better than expected) EBITA margin in Building Technology in H2 versus H1 (despite a 3% volume decline) gives us confidence that even with the expected volume headwind in 2024, Aalberts will be able to maintain margins close to the 2023 level with upside if the recovery starts in the latter part of 2024. In Industrial Technology we think Aalberts is overly cautiou...
We maintain our Outperform rating with an updated (DCF based) price target of €50.5 per share (was €46). The improved (and better than expected) EBITA margin in Building Technology in H2 versus H1 (despite a 3% volume decline) gives us confidence that even with the expected volume headwind in 2024, Aalberts will be able to maintain margins close to the 2023 level with upside if the recovery starts in the latter part of 2024. In Industrial Technology we think Aalberts is overly cautiou...
>Structural challenges remain - PostNL’s FY23 results underscored the structural tough environment the company operates in, as well as its relative inflexibility to address margin pressures. Inflationary pressures (tight labour market, minimum wage increases), unfavourable shifts in product and customer mix at both divisions and PostNL’s inability to price through all cost increases continue to impact the company’s results. Though we appreciate the increased focus on ...
Agfa advances sustainable innovation through strategic collaboration with VITO and EU funding for green hydrogen production Agfa advances sustainable innovation through strategic collaboration with VITO and EU funding for green hydrogen production Mortsel, Belgium - February 29, 2024 – 7:45 a.m. CETAgfa is accelerating sustainable technology advancements for ZIRFON membranes: Agfa strengthens its collaboration with renowned research and technology organization VITO for the development of a new generation of separator membranes for alkaline ...
Agfa bevordert duurzame innovatie door strategische samenwerking met VITO en EU-financiering voor groene waterstofproductie Agfa bevordert duurzame innovatie door strategische samenwerking met VITO en EU-financiering voor groene waterstofproductie Mortsel, België – 29 februari 2024 – 7:45 a.m. CETAgfa versnelt de duurzame technologische vooruitgang voor zijn ZIRFON-membranen: Agfa versterkt zijn samenwerking met de gerenommeerde onderzoeks- en technologieorganisatie VITO voor de ontwikkeling van een nieuwe generatie van scheidingsmembranen voor ...
Challenging market conditions impacted businesses more than expected last year. Hence, we cut FY23e revenues (-5%) and adj. EBIT (-48%). We foresee YoY revenues growth in Q4 both in Healthcare IT and DPC - Q4 has always been the strongest quarter for those. Management guided for a weak Q4 in Radiology. Overall, we expect Q4 profitability to be broadly in line with Q3.We foresee business conditions to remain tough for Agfa with limited improvements anticipated over the ST. Hence, we also cut FY24...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.